Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYes, many people do lose weight on lower doses of Wegovy — though how much depends on the individual, the dose, and how long treatment has been running. Wegovy (semaglutide) is titrated gradually through a prescribed schedule, and weight loss often begins during the early steps, not only at the top. These are prescription-only medicines; whether Wegovy is right for you, and at what dose, is a clinical decision made with a registered prescriber after a full assessment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
This is a question our prescribers hear most weeks. You started Wegovy, you've been through the 0.25mg starter period and moved up to 0.5mg, and you're watching the scales without quite knowing what to expect. The honest answer is that meaningful weight reduction at these early doses is possible, but it's not guaranteed for everyone at this stage, and that's by design.
The titration schedule exists primarily to let your digestive system adjust. Nausea, bloating and changes in appetite are most common in the first weeks after a dose increase, and stepping up slowly reduces how pronounced those effects are. That said, semaglutide begins acting on the GLP-1 receptors in your brain and gut from the very first injection, slowing how quickly food leaves your stomach and reducing hunger signals. Some people notice their portion sizes dropping and their interest in snacking fading even at 0.25mg. Others feel very little until they reach 1.7mg or 2.4mg. Both experiences are within normal range.
If you're curious about what the evidence says specifically for 0.5mg, the 0.5mg Wegovy weight loss page covers that step in detail. The short version: some loss is plausible, but the full picture builds over months.
The landmark STEP 1 trial, published in the New England Journal of Medicine, followed participants on semaglutide 2.4mg over 68 weeks and found an average body-weight reduction of around 15%. That headline figure is often quoted as if it belongs to the 2.4mg dose alone, but participants spent the first 16 weeks working through the titration steps to get there. The weight loss that accumulated during that period is folded into the average.
This matters because it tells you something useful: the body is already responding during the lower-dose phase. The degree varies widely between individuals, and the trial data doesn't isolate each dose step in the way a reader understandably hopes it might. What it does confirm is that sustained, progressive weight reduction across the full titration course is a real and documented outcome for many adults. Our guide to Wegovy doses walks through each step and what to expect from it.
One practical note: if you're comparing the cost of lower-dose treatment while thinking through whether to continue, our Wegovy price comparison guide sets out how private prescription costs in the UK are structured across the dose range.
Not everyone moves through the titration schedule at the same pace. Some people find side effects at a given step pronounced enough that their prescriber recommends holding at that dose for longer, sometimes an extra four weeks, sometimes more. This isn't a failure; it's the kind of personalised adjustment that a clinician makes when they're monitoring your progress properly.
There's also a smaller group of people who achieve their weight-management goals before reaching 2.4mg and, with clinical guidance, remain at a lower maintenance dose. The NHS semaglutide page notes that the schedule should always be followed as directed by your prescriber, the right dose for you is determined by how your body is responding, not by the maximum on the label.
If you started on the very first rung and want to understand what that phase typically involves, the starting dose of Wegovy page addresses that directly. And for the 1.7mg step (the one just before maintenance) this page on 1.7mg Wegovy covers what people commonly experience there.
Semaglutide works alongside a reduced-calorie diet and increased activity, that combination is part of the licensed indication, not a footnote. At lower doses, when appetite suppression may be milder, the lifestyle component can carry more of the load. Keeping protein intake adequate, staying well hydrated and building in some regular movement all support the process.
Muscle loss is a real consideration during weight reduction; strength-based activity helps preserve it. If you're finding the early weeks frustrating, it's worth noting that the biological changes happening at lower doses (improved insulin sensitivity, shifts in how your body manages blood sugar) are meaningful even when the scales aren't moving as fast as you'd like.
If you want to explore the full picture of how Wegovy works and what the treatment involves, the Wegovy overview page is a good place to start. And if you're ready to talk through your own situation with a prescriber, you're welcome to speak to our prescribers through a free consultation, reviewed the same day by a GPhC-registered prescriber, not a queue of automated responses.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.